Thyroid Cancer Genetics Study Finds New Mutations
By LabMedica International staff writers Posted on 08 May 2018 |
Image: A histopathology micrograph of anaplastic thyroid carcinoma (Photo courtesy of The Clayman Thyroid Cancer Center).
Anaplastic thyroid cancer (ATC) is a form of thyroid cancer, which has a very poor prognosis due to its aggressive behavior and resistance to cancer treatments. Its anaplastic cells have poor differentiation, including dedifferentiation.
A new study has defined the genetic landscape of advanced differentiated and anaplastic thyroid cancer and identified genetic alterations of potential diagnostic, prognostic and therapeutic significance.
Scientists at the University of Colorado Cancer Center (Aurora, CO, USA) and their colleagues recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers. Genetic profiles were generated and analyzed with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and FoundationOne (Foundation Medicine, Cambridge, MA, USA).
The investigators found that patients with ATC had more genetic alterations per tumor, and pediatric papillary thyroid cancer had fewer genetic alterations per tumor when compared to other thyroid cancer types. DNA mismatch repair deficit and activity of Apolipoprotein B mRNA Editing Catalytic Polypeptide (APOBEC) cytidine deaminases were identified as mechanisms associated with high mutational burden in a subset of differentiated and anaplastic thyroid cancers. Copy number losses and mutations of CDKN2A and CDKN2B, amplification of CCNE1, amplification of receptor tyrosine kinase genes KDR, KIT and PDGFRA, amplification of immune evasion genes CD274, PDCD1LG2 and JAK2 and activating point mutations in small GTPase RAC1 were associated with ATC.
Nikita Pozdeyev, MD, PhD, an assistant professor and lead author of the study, said, “Genetic analysis of early-stage thyroid cancers is most often not necessary as we successfully treat these tumors with surgery and radioactive iodine. But with distant metastases, genetic information becomes important for treatment. Because oncologists had sought this genetic information, our study is enriched for advanced cases.” The study was published on April 3, 2018, in the journal Clinical Cancer Research.
Related Links:
University of Colorado Cancer Center
Memorial Sloan Kettering Cancer Center
FoundationOne
A new study has defined the genetic landscape of advanced differentiated and anaplastic thyroid cancer and identified genetic alterations of potential diagnostic, prognostic and therapeutic significance.
Scientists at the University of Colorado Cancer Center (Aurora, CO, USA) and their colleagues recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers. Genetic profiles were generated and analyzed with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and FoundationOne (Foundation Medicine, Cambridge, MA, USA).
The investigators found that patients with ATC had more genetic alterations per tumor, and pediatric papillary thyroid cancer had fewer genetic alterations per tumor when compared to other thyroid cancer types. DNA mismatch repair deficit and activity of Apolipoprotein B mRNA Editing Catalytic Polypeptide (APOBEC) cytidine deaminases were identified as mechanisms associated with high mutational burden in a subset of differentiated and anaplastic thyroid cancers. Copy number losses and mutations of CDKN2A and CDKN2B, amplification of CCNE1, amplification of receptor tyrosine kinase genes KDR, KIT and PDGFRA, amplification of immune evasion genes CD274, PDCD1LG2 and JAK2 and activating point mutations in small GTPase RAC1 were associated with ATC.
Nikita Pozdeyev, MD, PhD, an assistant professor and lead author of the study, said, “Genetic analysis of early-stage thyroid cancers is most often not necessary as we successfully treat these tumors with surgery and radioactive iodine. But with distant metastases, genetic information becomes important for treatment. Because oncologists had sought this genetic information, our study is enriched for advanced cases.” The study was published on April 3, 2018, in the journal Clinical Cancer Research.
Related Links:
University of Colorado Cancer Center
Memorial Sloan Kettering Cancer Center
FoundationOne
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans